Literature DB >> 22002443

Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis.

Etresia van Dyk1, Pieter J Pretorius.   

Abstract

Hereditary tyrosinemia type 1 (HT1) is an autosomal recessive disorder affecting fumarylacetoacetate hydrolase (FAH), the last enzyme in the tyrosine catabolism pathway. The liver mosaicism observed in HT1 patients is due to the reversion to the wild type of one allele of the original point mutation in fah. It is generally accepted that these reversions are true back mutations; however, the mechanism is still unresolved. Previous reports excluded intragenic recombination, mitotic recombination, or homologous recombination with a pseudogene as possible mechanisms of mutation reversion in HT1. Sequence analysis did not reveal DNA motifs, tandem repeats or other sequence peculiarities that may be involved in mutation reversion. We propose the hypothesis that a point mutation instability mutator (PIN) phenotype brought about by the sustained stress environment created by the accumulating metabolites in the cell is the driver of the true back mutations in HT1. The metabolites accumulating in HT1 create a sustained stress environment by activating the extracellular signal-regulated kinase (ERK) and AKT survival pathways, inducing aberrant mitosis and development of death resistant cells, depleting glutathione, and impairing DNA ligase IV and possibly DNA polymerases δ and ε. This continual production of proliferative and stress-related survival signals in the cellular environment coupled with the mutagenicity of FAA, may instigate a mutator phenotype and could end in tumorigenesis and/or mutation reversion. The establishment of a PIN-mutator phenotype therefore not only seems to be a possible mechanism underlying the true back mutations, but also contributes to explaining the clinical heterogeneity seen in hereditary tyrosinemia type 1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002443     DOI: 10.1007/s10545-011-9401-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  40 in total

Review 1.  Factors that influence the mutagenic patterns of DNA adducts from chemical carcinogens.

Authors:  K Y Seo; S A Jelinsky; E L Loechler
Journal:  Mutat Res       Date:  2000-10       Impact factor: 2.433

2.  Hereditary tyrosinemia type 1 metabolites impair DNA excision repair pathways.

Authors:  E van Dyk; A Steenkamp; G Koekemoer; P J Pretorius
Journal:  Biochem Biophys Res Commun       Date:  2010-09-07       Impact factor: 3.575

Review 3.  Efficiency of carcinogenesis: is the mutator phenotype inevitable?

Authors:  Robert A Beckman
Journal:  Semin Cancer Biol       Date:  2010-10-08       Impact factor: 15.707

4.  Human cancers express a mutator phenotype.

Authors:  Jason H Bielas; Keith R Loeb; Brian P Rubin; Lawrence D True; Lawrence A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-15       Impact factor: 11.205

5.  Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I.

Authors:  Anne Bergeron; Rossana Jorquera; Diana Orejuela; Robert M Tanguay
Journal:  J Biol Chem       Date:  2005-11-29       Impact factor: 5.157

Review 6.  Genetic alterations and DNA repair in human carcinogenesis.

Authors:  Kathleen Dixon; Elizabeth Kopras
Journal:  Semin Cancer Biol       Date:  2004-12       Impact factor: 15.707

7.  Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.

Authors:  Y T Bliksrud; E Brodtkorb; P A Andresen; I E T van den Berg; E A Kvittingen
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

Review 8.  In vivo reversion to normal of inherited mutations in humans.

Authors:  R Hirschhorn
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

9.  DNA ploidy abnormalities in the liver of children with hereditary tyrosinemia type I. Correlation with histopathologic features.

Authors:  C Zerbini; D S Weinberg; K A Hollister; A R Perez-Atayde
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

10.  Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid.

Authors:  H S Edwards; J C Bremner; I J Stratford
Journal:  Int J Radiat Biol       Date:  1991-02       Impact factor: 2.694

View more
  4 in total

Review 1.  The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Authors:  Xiaomin Lou; Ju Zhang; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2014-05-05       Impact factor: 4.534

2.  Just like the rest of evolution in Mother Nature, the evolution of cancers may be driven by natural selection, and not by haphazard mutations.

Authors:  Ju Zhang; Xiaomin Lou; Lucas Zellmer; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Oncoscience       Date:  2014-09-22

Review 3.  Evidence for immortality and autonomy in animal cancer models is often not provided, which causes confusion on key issues of cancer biology.

Authors:  Xixi Dou; Pingzhen Tong; Hai Huang; Lucas Zellmer; Yan He; Qingwen Jia; Daizhou Zhang; Jiang Peng; Chenguang Wang; Ningzhi Xu; Dezhong Joshua Liao
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

Review 4.  Mutation or not, what directly establishes a neoplastic state, namely cellular immortality and autonomy, still remains unknown and should be prioritized in our research.

Authors:  Shengming Zhu; Jiangang Wang; Lucas Zellmer; Ningzhi Xu; Mei Liu; Yun Hu; Hong Ma; Fei Deng; Wenxiu Yang; Dezhong Joshua Liao
Journal:  J Cancer       Date:  2022-07-04       Impact factor: 4.478

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.